Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

American Heart Journal

Volumn 162, Issue 5, 2011, Pages 900-906

  Ariti, Cono A ^a   Cleland, John G F ^b   Pocock, Stuart J ^a   Pfeffer, Marc A ^c   Swedberg, Karl ^d   Granger, Christopher B ^e   McMurray, John J V ^f   Michelson, Eric L ^g   Östergren, Jan ^h   Yusuf, Salim ⁱ  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g ASTRAZENECA   (United Kingdom)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; PLACEBO;

ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DAY ALIVE AND OUT OF HOSPITAL; FOLLOW UP; FUNCTIONAL STATUS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; LINEAR MODELS; MALE; MODELS, STATISTICAL; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TREATMENT OUTCOME; UNITED STATES;

EID: 81255168042     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.08.003     Document Type: Article

References (15)

1. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure Am J Cardiol 83 1999 1A 38A
2. J.G. Cleland How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey Eur J Heart Fail 4 2002 243 247 (Pubitemid 35190346)
3. L. Zanolla, and P. Zardini Selection of endpoints for heart failure clinical trials Eur J Heart Fail 5 2003 717 723 (Pubitemid 38198058)
4. H. Skali, M.A. Pfeffer, and J. Lubsen Variable impact of combining fatal and nonfatal end points in heart failure trials Circulation 114 2006 2298 2303 (Pubitemid 44801489)
5. J.D. Neaton, G. Gray, and B.D. Zuckerman Key issues in end point selection for heart failure trials: composite end points J Card Fail 11 2005 567 575 (Pubitemid 41463726)
6. J.G. Cleland, A. Charlesworth, and J. Lubsen A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET) J Am Coll Cardiol 47 2006 1603 1611
7. J. Cohn, J.G. Cleland, and J. Lubsen Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality? J Card Fail 15 2009 199 205
8. B.E. Sobel, and C.D. Furberg Surrogates, semantics, and sensible public policy Circulation 95 1997 1661 1663 (Pubitemid 27142830)
9. G. Olsson, J. Lubsen, and G.A. van Es Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity Br Med J (Clin Res Ed) 292 1986 1491 1493 (Pubitemid 16122610)
10. C.B. Granger, J.J. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776 (Pubitemid 37093917)
11. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771 (Pubitemid 37093916)
12. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766 (Pubitemid 37093915)
13. K. Swedberg, M. Pfeffer, and C. Granger Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators J Card Fail 5 1999 276 282 (Pubitemid 29449267)
14. S. Yusuf, M.A. Pfeffer, and K. Swedberg Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781 (Pubitemid 37093918)
15. J.A. Barber, and S.G. Thompson Analysis of cost data in randomized trials: an application of the non-parametric bootstrap Stat Med 19 2000 3219 3236